Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

A recent study revealed that early-life exposure to tobacco significantly elevates the risk of developing idiopathic ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

Katie Price shared a health update with fans after revealing she has undergone checks on her lungs. The former glamour model said she was concerned vaping had affected her lungs and also wanted to err ...